Xcout IntelSign inSubscribe

IM Cannabis Corp. competitors & alternatives

IMCCPharmaceuticalsTel Aviv, Israel

The 12 closest competitors and alternatives to IM Cannabis Corp. among pharmaceuticals companies — ranked by similarity to what IM Cannabis Corp. actually does, not by market-cap band.

$3.1MMarket cap
95Employees
12Competitors listed

Subscribe to see IM Cannabis Corp.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event

About IM Cannabis Corp.

IM Cannabis Corp. specializes in the cultivation, production, and provision of medicinal cannabis goods throughout international markets such as Israel, Germany, and Canada. The company offers a range of cannabis products, including flowers and specifically formulated cannabis extracts, marketed under its IMC brand. Furthermore, it supplies dried flower, pre-rolled products, and compressed hashish via its WAGNERS and Highland Grow labels. IM Cannabis Corp. serves a broad customer base, addressing the needs of both medical patients and adult recreational consumers. Its corporate headquarters are located in Tel Aviv-Yafo, Israel.

IM Cannabis Corp. at a glance

IM Cannabis Corp. is a pharmaceuticals company headquartered in Tel Aviv, Israel. It is publicly listed (IMCC) with a market capitalisation of $3.1M. Xcout tracks 13 named people at IM Cannabis Corp., including Oren Shuster (Chief Executive Officer & Executive Director).

IM Cannabis Corp. leadership

  • Oren ShusterChief Executive Officer & Executive Director
  • Richard BallaChief Executive Officer of Adjupharm
  • Eyal FisherChief Executive Officer of the IMC Holdings
  • Asi LeviChief Financial Officer
  • Anna TarankoDirector Investor & Public Relations
  • Michal Lebovitz NissimovExecutive Officer

7 more named people on record for IM Cannabis Corp., with roles, board committees and tenure — see the full roster →

Top 12 IM Cannabis Corp. competitors

Ranked by semantic similarity — how close each company is to IM Cannabis Corp. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.

TEVATEVA · PharmaceuticalsTel Aviv, Israel
63% matchPublic

Similar pharmaceuticals company

Teva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, and biopharmaceutical products throughout North America, Europe, and various international markets. The company's diverse product range includes sterile items, hormones, potent drugs, and cytotoxic agents, available in numerous forms like tablets, capsules, injectable solutions, inhalable preparations, liquids, transdermal patches, topical ointments, and creams. Additionally, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). The firm prioritizes several key therapeutic domains: central nervous system disorders, pain management, respiratory ailments, and oncology. In the central nervous system sector, prominent products include Copaxone, intended for relapsing forms of multiple sclerosis; AJOVY, prescribed for preventing migraines; and AUSTEDO, which targets tardive dyskinesia and chorea linked to Huntington's disease. For respiratory conditions, Teva offers medications such as ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick, all designed to treat asthma and chronic obstructive pulmonary disease. The oncology portfolio features therapies like Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited is also engaged in a collaboration with MedinCell to advance and commercialize multiple long-acting injectable formulations, notably a risperidone suspension for individuals affected by schizophrenia. The company was established in 1901 and its primary headquarters are located in Tel Aviv-Yafo, Israel.

Market cap$45.8B
Employees37,000
TEVA competitors & alternatives →
InMed Pharmaceuticals Inc.INM · PharmaceuticalsVancouver, Canada
68% matchPublic

Similar pharmaceuticals company

InMed Pharmaceuticals Inc. operates as a clinical-stage pharmaceutical firm, concentrating its efforts on the investigation and creation of therapeutic solutions derived from cannabinoids. Its primary product, INM-755, is a cannabinol-infused topical cream that is currently progressing through its second Phase I clinical trial for the management of epidermolysis bullosa. Beyond this lead candidate, the company is also developing INM-088, which is undergoing preclinical studies for glaucoma treatment, and INM-405, intended for pain relief. Its broader development pipeline encompasses cannabinoid-based interventions for a variety of medical conditions, with a particular focus on dermatological and ocular disorders. Furthermore, InMed is involved in critical IND-enabling pharmacology and preclinical toxicology research. It is also pioneering IntegraSyn, an innovative integrated biosynthesis approach designed to produce pharmaceutical-grade cannabinoids efficiently. The company maintains a research partnership with BayMedica Inc. to collaborate on the formulation and assessment of novel cannabinoid therapeutics. Established in 1981, the company is headquartered in Vancouver, Canada. It operated under the name Cannabis Technologies Inc. before officially rebranding as InMed Pharmaceuticals Inc. in October 2014.

Market cap$7.3M
Employees13
InMed Pharmaceuticals Inc. competitors & alternatives →

Analyze another company

Search any company we track to see its competitive set.

Or describe a company

Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.

See the full profile of IM Cannabis Corp. and its market

Funding, investors, tech stack, hiring signals, leadership and corporate events — for IM Cannabis Corp.and every competitor above — in one live dashboard.

Subscribe to Xcout Intel →